Kelleher Raymond J. 4

What Happened

• Raymond J. Kelleher, a director of BridgeBio Oncology Therapeutics, Inc. (BBOT), received a grant (reported as a derivative award) covering 31,675 shares on 2026-06-16. The Form 4 shows an acquisition at a reported price of $0.00 (total reported value $0.00). The award is a stock option (derivative) rather than an immediate share purchase.

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-18.
• Transaction type/code: Award/Grant (derivative).
• Shares/units granted: 31,675; reported price: $0.00 (total reported $0.00).
• Shares owned after transaction: Not specified in this Form 4.
• Notable footnote: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the next Annual Meeting of Stockholders, subject to Kelleher’s continued service.
• Filing timeliness: No late filing flag indicated; Form 4 was filed two days after the transaction date.

Context

• This was a grant of an option to acquire shares (a derivative award), not an exercise or sale; no cash was paid by the insider at the time of grant. Such awards are commonly used for director compensation and will only result in actual shares if/when the option vests and is exercised under the stated terms.